Rugo, H.S.; Bardia, A.; Schmid, P.; Tolaney, S.M.; Dasgupta, A.; Kaushik, A.; Verret, W.; Gosset, M.; Brufsky, A.; Cortés, J.;
et al. Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer. Curr. Oncol. 2025, 32, 169.
https://doi.org/10.3390/curroncol32030169
AMA Style
Rugo HS, Bardia A, Schmid P, Tolaney SM, Dasgupta A, Kaushik A, Verret W, Gosset M, Brufsky A, Cortés J,
et al. Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer. Current Oncology. 2025; 32(3):169.
https://doi.org/10.3390/curroncol32030169
Chicago/Turabian Style
Rugo, Hope S., Aditya Bardia, Peter Schmid, Sara M. Tolaney, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Marine Gosset, Adam Brufsky, Javier Cortés,
and et al. 2025. "Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer" Current Oncology 32, no. 3: 169.
https://doi.org/10.3390/curroncol32030169
APA Style
Rugo, H. S., Bardia, A., Schmid, P., Tolaney, S. M., Dasgupta, A., Kaushik, A., Verret, W., Gosset, M., Brufsky, A., Cortés, J., & Marmé, F.
(2025). Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer. Current Oncology, 32(3), 169.
https://doi.org/10.3390/curroncol32030169
